ESBA-212

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameESBA-212

Drug Alias NameBeta-Amyloid Antibody Fragment (ESBATech)ESBA-212

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment

Mechanisms of ActionBeta amyloid A4 protein inhibitors

TargetsBeta amyloid A4 protein

Therapy Area/IndicationsAlzheimer Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesEsbatech Ag

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesEsbatech Ag

Active IndicationsN/A

Inactive IndicationsAlzheimer Disease

Other Information

ATC CodeN/A